FDA Approves Pfizer's Hympavzi for Hemophilia A and B: A Milestone in Treatment Advancements

The FDA's approval of Hympavzi (marstacimab-hncq) marks a pivotal advancement for patients with hemophilia A and B. Developed by Pfizer, Hympavzi is the first of its kind in the U.S. as a non-factor, once-weekly treatment that targets the tissue factor pathway inhibitor to enhance blood clotting[1][2]. It is administered subcutaneously using a pre-filled pen or syringe, offering a significant reduction in the annualized bleeding rate compared to both on-demand and regular prophylaxis therapies[2][3]. Despite its efficacy, the treatment comes with warnings for thromboembolic events and other side effects, including injection site reactions and headache[1][3].